Upadacitinib in active non-radiographic axial spondyloarthritis: 2-year data from the phase 3 SELECT-AXIS 2 study
Arthritis Research & Therapy · 2025
DOI: 10.1186/s13075-024-03441-3 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Arthritis Research & Therapy, 2025. Verfasst von Filip Van den Bosch und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine and Pediatrics, VIB Center for Inflammation Research, Ghent University, Ghent, Belgium. filip.vandenbosch@ugent.be. Hauptthemen laut MEDLINE: Heterocyclic Compounds, 3-Ring, Axial Spondyloarthritis, Antirheumatic Agents. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AbbVie.
Abstract (Originalsprache)
Background
In SELECT-AXIS 2, upadacitinib improved the signs and symptoms of active non-radiographic axial spondyloarthritis (nr-axSpA) through 52 weeks versus placebo and was well tolerated. Here, we evaluated the efficacy and safety of upadacitinib through 2 years.
Methods
The study enrolled eligible adult patients with a clinical diagnosis of nr-axSpA who met the 2009 Assessment of SpondyloArthritis international Society (ASAS) classification criteria and had objective signs of active inflammation on magnetic resonance imaging (MRI) of sacroiliac joints and/or high-sensitivity C-reactive protein. Patients were randomized 1:1 to receive double-blinded treatment with upadacitinib 15 mg once daily (QD) or placebo for 52 weeks, after which all patients received open-label treatment with upadacitinib 15 mg QD. Efficacy results over 104 weeks were reported as observed (AO) and either AO with non-responder imputation (AO-NRI; binary endpoints) or AO with mixed-effect model for repeated measures (continuous endpoints). Treatment-emergent adverse events (TEAEs) were summarized through week 104.
Results
Of 313 patients randomized and treated, 224 (continuous upadacitinib n = 117; placebo/upadacitinib n = 107) completed 104 weeks of treatment. In patients who received continuous upadacitinib, sustained improvement was observed through 2 years of treatment across efficacy endpoints including disease activity, pain, function, enthesitis, quality of life, and MRI measures of inflammation. At week 104, 57.1%, 59.0%, and 31.4% of patients achieved ASAS40 response, and low disease activity and inactive disease (as defined by Axial Spondyloarthritis Disease Activity Score), respectively (AO-NRI); week 104 outcomes were generally similar in patients who initially received placebo and were switched to upadacitinib at week 52. In total, 286 patients were exposed to ≥ 1 dose of upadacitinib, comprising 378.3 patient-years (PY) of exposure. Upadacitinib was generally well tolerated, with exposure-adjusted event rates (EAERs) for TEAEs, serious adverse events (AEs), and AEs leading to study drug discontinuation of 207.5, 8.7, and 5.3 events/100 PY, respectively. EAERs of TEAEs of special interest were broadly consistent with those reported through week 52.
Conclusions
Treatment with upadacitinib demonstrated consistent improvement and maintenance of treatment effect across efficacy endpoints through 2 years; no new safety signals were identified with additional exposure.
Trial registration
NCT04169373.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine and Pediatrics, VIB Center for Inflammation Research, Ghent University, Ghent, Belgium. filip.vandenbosch@ugent.be.
- Division of Arthritis & Rheumatic Diseases, Oregon Health & Science University, Portland, OR, USA.
- Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité Universitätsmedizin, Berlin, Germany.
- Department of Medicine, University of Alberta, Edmonton, AB, Canada.
- Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands.
- Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea.
Förderung
- AbbVie
Zitieren
APA
Van den Bosch, F., Deodhar, A., Poddubnyy, D., Maksymowych, W. P., van der Heijde, D., Kim, T. H., Kishimoto, M., Baraliakos, X., Bu, X., Lagunes-Galindo, I., Song, I. H., Wung, P., Kato, K., & Shmagel, A. (2025). Upadacitinib in active non-radiographic axial spondyloarthritis: 2-year data from the phase 3 SELECT-AXIS 2 study. Arthritis Research & Therapy. https://doi.org/10.1186/s13075-024-03441-3
Vancouver
Van den Bosch F, Deodhar A, Poddubnyy D, Maksymowych WP, van der Heijde D, Kim TH, et al. Upadacitinib in active non-radiographic axial spondyloarthritis: 2-year data from the phase 3 SELECT-AXIS 2 study. Arthritis Research & Therapy. 2025. doi:10.1186/s13075-024-03441-3
BibTeX
@article{VandenBosch2025,
author = {Van den Bosch, Filip and Deodhar, Atul and Poddubnyy, Denis and Maksymowych, Walter P and van der Heijde, Désirée and Kim, Tae-Hwan and Kishimoto, Mitsumasa and Baraliakos, Xenofon and Bu, Xianwei and Lagunes-Galindo, Ivan and Song, In-Ho and Wung, Peter and Kato, Koji and Shmagel, Anna},
title = {Upadacitinib in active non-radiographic axial spondyloarthritis: 2-year data from the phase 3 SELECT-AXIS 2 study},
journal = {Arthritis Research & Therapy},
year = {2025},
doi = {10.1186/s13075-024-03441-3}
}
EUVIMED